Pennsylvania HB2529 amends the Controlled Substance, Drug, Device and Cosmetic Act to include medetomidine in Schedule III and mandates secure.
Pennsylvania HB2529 amends the Controlled Substance, Drug, Device and Cosmetic Act to classify medetomidine as a Schedule III controlled substance. It specifies conditions under which medetomidine is not considered a controlled substance, including its use in approved animal drugs and certain manufacturing processes. The bill also mandates that veterinarians comply with secure storage requirements for medetomidine and xylazine, aligning with provisions in the Pharmacy Act. This act takes effect immediately upon enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.